Salvagno L, Sorarù M, Busetto M, Puccetti C, Sava C, Endrizzi L, Giusto M, Aversa S, Chiarion Sileni V, Polico R, Bianco A, Rupolo M, Nitti D, Doglioni C, Lise M
Divisione di Oncologia Medica, Centro Oncologico Regionale, Padua.
Tumori. 1999 Mar-Apr;85(2):113-21.
The stomach is the most common site of primary extranodal non-Hodgkin's lymphoma (NHL) and no agreement has been reached so far on the best therapeutic approach. The main objects of this study were to report the long-term results and to evaluate the importance of some possible prognostic factors in a large series of patients. NHL was considered primary gastric if the main symptoms at presentation were those of gastric disease.
We analyzed 252 consecutive patients treated between 1980 and 1993 in five hospitals in north-east Italy. According to the Working Formulation, 98 patients had low grade lymphoma, 59 intermediate grade (D to F), 81 G or high grade and 14 were not classified. The patients were divided into two groups: one including patients with limited disease (localized to the stomach or perigastric lymph nodes: 165 patients) and one including those with advanced disease (87 patients). The treatment consisted of surgery, chemotherapy, radiotherapy or combinations of these. Sixteen patients received only supportive therapy.
The five-year overall survival was 65.4%: 80.3% for patients with limited disease and 36.7% for those with advanced disease (P < 0.0001). Among the limited disease patients the five-year survival was 84.4% for those treated with gastrectomy alone and 88.7% for those who received also adjuvant chemotherapy (P = 0.11). However, while chemotherapy did not improve survival in low grade NHL, it seemed to produce a better survival in the intermediate and high grade groups (P = 0.06). Twelve patients were treated with primary chemotherapy and the five-year survival was 71.2%. In multivariate regression analysis the most important variable for overall survival was surgery for the whole group of 252 patients (P < 0.0001), while it was age for the group with limited disease (P = 0.0008).
Surgery alone can be curative for most patients with gastric lymphoma limited to the stomach or to the perigastric lymph nodes; surgery followed by chemotherapy seems to produce better results than surgery alone in intermediate and high grade lymphomas. Also a non-surgical approach with first-line chemotherapy is associated with a high rate of complete remissions and five-year survival. In advanced disease the five-year survival is similar to that of nodal NHL.
胃是原发性结外非霍奇金淋巴瘤(NHL)最常见的发病部位,目前对于最佳治疗方法尚未达成共识。本研究的主要目的是报告长期结果,并评估一系列大量患者中一些可能的预后因素的重要性。如果患者就诊时的主要症状为胃部疾病,则将NHL视为原发性胃淋巴瘤。
我们分析了1980年至1993年间在意大利东北部五家医院接受治疗的252例连续患者。根据工作分类法,98例患者为低度淋巴瘤,59例为中度(D至F级),81例为G级或高度淋巴瘤,14例未分类。患者分为两组:一组包括疾病局限的患者(局限于胃或胃周淋巴结:165例患者),另一组包括疾病晚期的患者(87例患者)。治疗包括手术、化疗、放疗或这些方法的联合应用。16例患者仅接受支持性治疗。
五年总生存率为65.4%:疾病局限的患者为80.3%,疾病晚期的患者为36.7%(P<0.0001)。在疾病局限的患者中,单纯接受胃切除术的患者五年生存率为84.4%,接受辅助化疗的患者为88.7%(P=0.11)。然而,虽然化疗在低度NHL中未改善生存率,但在中度和高度组中似乎能产生更好的生存率(P=0.06)。12例患者接受了一线化疗,五年生存率为71.2%。在多因素回归分析中,对于252例患者的整个队列,总体生存的最重要变量是手术(P<0.0001),而对于疾病局限的组,最重要变量是年龄(P=0.0008)。
对于大多数局限于胃或胃周淋巴结的胃淋巴瘤患者,单纯手术即可治愈;在中度和高度淋巴瘤中,手术加化疗似乎比单纯手术效果更好。一线化疗的非手术方法也与高完全缓解率和五年生存率相关。在疾病晚期,五年生存率与结内NHL相似。